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Introduction {#sec007}
============

Opioid use is responsible for an important increase in premature mortality in young and middle-aged adults in the US \[[@pmed.1002974.ref001]\] and Canada \[[@pmed.1002974.ref002]\], 2 of the countries with the highest per capita prescription opioid consumption in Western industrialized nations \[[@pmed.1002974.ref003]\]. Other countries such as England have seen similar rates of increase in prescription opioid use but not concomitant increases in mortality rates, likely related in part to better access to addiction treatment and more oversight of prescription opioids \[[@pmed.1002974.ref004]\]. Across all of these jurisdictions, there is increasing opioid use by pregnant women, and while little is known about associated maternal mortality, a recent study using data from 22 US states and the District of Columbia reports a higher than 3-fold increase from 2007 to 2017 in opioid-related deaths in women during or within the first year after pregnancy \[[@pmed.1002974.ref005]\].

Population-based surveillance of opioid use during pregnancy is difficult given the lack of prescription medication data in many jurisdictions and the challenges in measuring illicit use. Neonatal abstinence syndrome (NAS) is coded in the infant birth hospitalization record and offers a widely used but imperfect proxy measure of maternal opioid use during pregnancy. NAS manifests typically within hours to 1 to 2 days of delivery with autonomic, gastrointestinal, and neurologic symptoms of drug withdrawal in the infant that often require prolonged postnatal care \[[@pmed.1002974.ref006]\]. Not all infants exposed to opioids in utero will experience NAS \[[@pmed.1002974.ref007],[@pmed.1002974.ref008]\]. In trial and observational settings, approximately half of women receiving methadone or buprenorphine maintenance therapy in pregnancy gave birth to an infant with signs of NAS \[[@pmed.1002974.ref007]\], and estimates of up to 91% have been reported in other groups of women with chronic opioid use \[[@pmed.1002974.ref006]\]. The incidence of NAS rose dramatically between the early 2000s and 2014 in the US (from 28 to 144 per 10,000 births) \[[@pmed.1002974.ref009]\] and Canada (from 18 to 54 per 10,000 live births) \[[@pmed.1002974.ref010]\], but remained relatively stable in Australia and England \[[@pmed.1002974.ref011],[@pmed.1002974.ref012]\].

Mothers of infants with NAS represent a heterogeneous group including those using prescription opioids and opioid agonists for analgesia, those on medically supervised maintenance treatment for dependence, and those using illicit opioids \[[@pmed.1002974.ref012]\]. Overall social disadvantage and opioid use are inextricably linked, and many women who misuse these drugs are at greater risk of adversity, including deprivation, violence and abuse, and use of other substances \[[@pmed.1002974.ref013]\]. All of these factors impact negatively on maternal health and may diminish parenting capacity \[[@pmed.1002974.ref014]\]. Improving maternal health and preventing premature maternal mortality in this population is therefore critical for both mothers and their children. Pregnancy and delivery care are opportunities to improve access to addiction and supportive services. While public health programs such as nurse home visits tend to focus on pregnancy and the early postpartum period \[[@pmed.1002974.ref015]\], it is largely unknown whether this is the only period of risk for poor outcomes for mothers who use opioids in pregnancy.

Evidence on mortality for mothers who use opioids in pregnancy is limited but consistently shows increased rates around the time of delivery ([Table 1](#pmed.1002974.t001){ref-type="table"}) \[[@pmed.1002974.ref005],[@pmed.1002974.ref016]--[@pmed.1002974.ref018]\]. Very high rates of longer-term maternal mortality have been reported in 2 older studies (1 Australian and 1 Finnish) \[[@pmed.1002974.ref019],[@pmed.1002974.ref020]\], but these studies may not reflect the current opioid epidemic in North America or the UK \[[@pmed.1002974.ref004]\]. Recent estimates of mortality from a meta-analysis of people with substance misuse disorder and homeless and prison populations reported a standardized mortality ratio for women of 11.9 (95% CI 10.4--13.3), which was higher than the equivalent figure for men (7.9; 95% CI 7.0--8.7) \[[@pmed.1002974.ref021]\]. There is a dearth of information about long-term health outcomes for women---particularly mothers---with opioid use, which is an important knowledge gap given rising rates of prescription and illicit opioid use. Pregnancy can be seen as a window of opportunity for identifying and managing substance misuse and the implications for parenting capacity.

10.1371/journal.pmed.1002974.t001

###### Mortality rates from 6 population-based studies of women with substance misuse during pregnancy.

![](pmed.1002974.t001){#pmed.1002974.t001g}

  Study (country)                                           Study design (study years)                                Study population                                                                                                                                              Duration of follow-up                                       Number of participants       Number of deaths     Mortality rate                                                                                                             Mortality rate ratio
  --------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  ***Long-term mortality***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Kahila et al. 2010 \[[@pmed.1002974.ref020]\] (Finland)   Registry-based retrospective case--control (1992--2001)   Women living in Helsinki metropolitan area who gave birth between 1992 and 2001 and were referred to a specialist alcohol/substance misuse antenatal clinic   Mean of 9.4 (cases) and 10.1 (controls) years               2,316 (524 cases)            46 (42 cases)        8.52 (cases) and 0.22 (controls) per 1,000 person-years                                                                    OR: 38 (95% CI 14--108)
  Hser et al. 2012 \[[@pmed.1002974.ref022]\] (US)          Prospective cohort study (2000--2010)                     Pregnant or parenting women assessed and admitted to 40 drug treatment programs in California between 2000 and 2002                                           8--10 years                                                 4,447                        194                  4.47 per 1,000 person-years                                                                                                SMR: 8.4 (95% CI 7.2--9.6)
  ***Short-term mortality***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wolfe et al. 2005 \[[@pmed.1002974.ref018]\] (US)         Linked discharge, birth, and death cohort (1991--1998)    Mother and newborn pairs between 1991 and 1998 in California with drug and/or alcohol use indication as discharge diagnostic codes during pregnancy           Death ≤ 72 hours after delivery                             4,536,701 (54,290 cases)     1,944 (62 cases)     Unknown/not stated                                                                                                         RR: 2.7 (95% CI 2.1--3.5)
  Whiteman et al. 2014 \[[@pmed.1002974.ref017]\] (US)      Cross-sectional analysis (1998--2009)                     Women with a pregnancy-related hospital discharge between 1998 and 2009 with indication of opioid use during pregnancy on the discharge record                Death during the delivery hospital stay                     55,781,965 (138,224 cases)   Unknown/not stated   0.8 (cases) and 0.1 (controls) per 1,000 pregnancy-related discharges                                                      OR: 5.9 (95% CI 3.7--9.3)
  Maeda et al. 2014 \[[@pmed.1002974.ref016]\] (US)         Cross-sectional analysis (1998--2011)                     Women with a delivery admission between 2007 and 2011 with indication of opioid abuse or dependence during pregnancy on the discharge record                  Death during the delivery hospital stay                     20,517,479 (60,994 cases)    1,331 (20 cases)     0.03 (cases) and 0.006 (controls) per 100 delivery hospitalizations                                                        Adjusted OR: 4.6 (95% CI 1.8--12.1)
  Gemmill et al. 2019 \[[@pmed.1002974.ref005]\] (US)       Retrospective cohort study (2007--2016)                   Women aged 15--49 years with a pregnancy-associated death between 2007 and 2016 across 22 US states and the District of Columbia                              Death while pregnant or within 1 year of end of pregnancy   Unknown/not stated           Unknown/not stated   Mortality per 100,000 live births: 31.7 in 2007 to 42.3 in 2016 (all-cause); 1.3 in 2007 to 4.2 in 2016 (opioid-related)   Unknown/not stated

Non-population-based studies \[[@pmed.1002974.ref019],[@pmed.1002974.ref023]--[@pmed.1002974.ref025]\] or studies that examined opioid use but not during pregnancy \[[@pmed.1002974.ref026]--[@pmed.1002974.ref029]\] were excluded.

OR, odds ratio; RR, relative risk; SMR, standardized mortality ratio.

In this study, we capitalize on linked population-based maternal--infant healthcare records and mortality files in 2 jurisdictions (England and Ontario, Canada). Both have similar healthcare systems, including universal access to healthcare and similar postnatal public health programs that focus predominantly on the year after birth. We hypothesized that NAS mothers would have significantly higher rates of mortality than control mothers. We aimed to quantify this excess mortality, investigating all-cause mortality as the primary outcome and cause-specific mortality as secondary outcomes. We present all-cause mortality in relation to some key maternal characteristics at the time of birth, to identify clinically useful sub-groups with poor prognostic outcomes and to guide opioid misuse policy and research.

Methods {#sec008}
=======

An analytic plan was written and approved before starting statistical analyses ([S1 Text](#pmed.1002974.s003){ref-type="supplementary-material"}). All analyses were undertaken as planned and reported, with the exception of the removal of comorbidity adjustment in the Cox proportional hazards model (see section on statistical analysis below) as a result of feedback from peer review. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S2 Text](#pmed.1002974.s004){ref-type="supplementary-material"}).

Cohort {#sec009}
------

We derived whole-region population-based cohorts of mothers aged 12 to 49 years and their live born infants delivered between April 1, 2002, and December 31, 2012, in England and Ontario, Canada. This period coincides with a steep increase in opioid use, particularly in Canada. The cohorts used longitudinal hospital discharge records for mothers (back to April 1, 1997, for some covariates) linked to hospitalization records for the infant. Mortality registration records were linked to hospital records for the mother and infant. In England, de-identified data on inpatient admissions for all National Health Service (NHS) hospitals linked to Office for National Statistics mortality data were obtained from NHS Digital, linked between mother and infant using previously reported methods \[[@pmed.1002974.ref030]\], and analyzed within the UCL Data Safe Haven, England \[[@pmed.1002974.ref031]\]. In Ontario, hospital discharge records were obtained from the Canadian Institute for Health Information Discharge Abstract Database and the Ontario Mental Health Reporting System. Cause of death information was taken from the Office of the Registrar General's vital statistics database (data available only until 2014), and demographic information captured from the 2006 Canadian Census and the Registered Persons Database (which includes date of death). Canadian datasets were linked using unique coded identifiers common across all aforementioned datasets and analyzed at ICES in Toronto, Ontario, Canada. We restricted the cohort to singleton births, and if a woman had more than 1 live birth delivery during the study period, 1 delivery was chosen at random as the focus of the study, i.e., a delivery date was selected at random and used as the entry point for the mother (referred to as the index delivery), and all other deliveries were ignored.

In both jurisdictions, infants with a diagnosis of NAS were identified using International Classification of Diseases and Related Health Problems---10^th^ Revision (ICD-10) codes P96.1 (neonatal withdrawal symptoms from maternal use of drugs of addiction) or P04.4 (newborn \[suspected to be\] affected by maternal use of drugs of addiction) recorded during the delivery admission or subsequent readmission within 14 days of birth \[[@pmed.1002974.ref011]\]. The ICD-9 equivalent to P96.1 has been shown to have high sensitivity (88.1%; 95% CI 83.3%--91.7%) and specificity (97.0%; 95% CI 93.8%--98.5%) and a positive predictive value of 91.2% (95% CI 86.8%--94.2%) for measuring NAS \[[@pmed.1002974.ref032]\] and is used by the US Agency for Healthcare Research and Quality \[[@pmed.1002974.ref033]\]. We included P04.4 as it is often used for opioid withdrawal in both jurisdictions. In a sample of all Ontario women giving birth in hospital from 2014 to 2017 (*n* = 464,400), during which time all prescription opioids were registered, over 56% of women whose infant had a diagnosis of P04.4 had either a prescription for opioids or opioid agonists, or a healthcare encounter related to opioid use during pregnancy (personal communication, A. Camden, University of Toronto, September 4, 2019). In our study, NAS was ascertained by P96.1 in 83% of cases in England and 65.7% in Ontario. The English maternal cohort was identified using linked data for singleton babies and mothers, corresponding to 96% of all live births in England within the study period. Mothers and babies were matched deterministically using data on hospital, general practitioner practice, maternal age, birthweight, gestation, birth order, and sex, or probabilistically using additional data including admission dates, ethnicity, and partial postal code \[[@pmed.1002974.ref034]\]. Ontario mothers were identified using a unique number linking all newborn and maternal hospital records that is assigned at the delivery hospitalization.

Outcomes and covariates {#sec010}
-----------------------

The main outcome was all-cause mortality measured from April 1, 2002, to March 31, 2016, derived from linked death registrations. Cause-specific mortality was available only up until December 31, 2014, for Ontario. Cause-specific deaths were classified as avoidable (defined as preventable, amenable to care, or both), unavoidable (as specified by the UK's Office for National Statistics) \[[@pmed.1002974.ref035]\], or cancer (avoidable and unavoidable).

Longitudinal hospital records were used to derive baseline characteristics at the index delivery including maternal age (12--19 years, 20--34 years, and 35+ years); time since last birth (defined as no previous births \[with lookback to April 1, 1997, only\], \<2 years, 2--5 years, and 6+ years); neighbourhood income quintile; urban or rural residence; pregnancy-related outcomes: cesarean delivery, gestational age at delivery (\<34 weeks, 34--36 weeks, and 37+ weeks), gestational hypertension, pre-eclampsia/eclampsia, and gestational diabetes; neonatal mortality (death within 28 days of birth); and infant discharge from hospital to social services. We excluded observations with extreme values, including women aged \<12 years or \>49 years at the date of delivery. Missing values for neighbourhood income quintile (*n* = 3,850 \[0.41%\] for Ontario; *n* = 24,067 \[0.57%\] for England) were categorized into the lowest income quintile, and missing area of residence information (*n* = 151 \[0.02%\] for Ontario; *n* = 22,970 \[0.54%\] for England) was categorized into the urban area of residence. In Ontario, these missing data are suppressed for neighbourhoods with high rates of residential instability, which are predominantly low income and urban.

Baseline maternal morbidities were measured for a 5-year lookback period using all diagnostic codes in all hospital admissions within this period to assign the Charlson comorbidity index (Deyo version) (0, 1, or 2+ comorbid conditions) and to identify hospitalizations related to (i) any psychiatric condition, (ii) addiction-related conditions, and (iii) other mental health conditions. We chose the Deyo version of the Charlson comorbidity index as it has been most widely used in maternal mortality studies and, unlike other indices, has been validated on longer-term mortality, although not in pregnant women \[[@pmed.1002974.ref036],[@pmed.1002974.ref037]\]. [S1](#pmed.1002974.s001){ref-type="supplementary-material"} and [S2](#pmed.1002974.s002){ref-type="supplementary-material"} Tables list diagnostic codes and provide definitions for neighbourhood income quintile and urban or rural residence.

Statistical analysis {#sec011}
--------------------

### Descriptive statistics {#sec012}

We compared mothers with an infant affected by NAS and controls within each jurisdiction. We compared baseline characteristics using Pearson's chi-squared test (categorical variables) and ANOVA (continuous variables).

### All-cause mortality {#sec013}

Our primary outcome was all-cause mortality of mothers after the birth of an infant with NAS, relative to control mothers. Survival analysis for time to all-cause mortality was modelled using multivariable Cox regression, with proportionality of hazards assessed by Schoenfeld residuals and log--log plots, and included all deaths to the end of the study period. Crude and adjusted hazard ratios were produced that were adjusted only for maternal age group at delivery to describe the extent of the mortality gap between NAS mothers and controls. We explicitly did not attempt to adjust models for other covariates as we do not attempt to infer causality. This is primarily because our data reflect maternal opioid use at a single time point (delivery). Thus we are unable to examine the direction of effect for key factors such as mental illness or socioeconomic status that may either confound the association between opioid use and death or lie on the causal pathway. We initially adjusted the model for the Charlson comorbidity index but as a result of peer review do not report these estimates because of our aim to not make causal inferences. Crude and adjusted survival curves were plotted to estimate the absolute risk of mortality at 5 and 10 years after birth. We derived 95% confidence intervals for mortality at 5 and 10 years after delivery through log--log transformation of the survival function and computed *p*-values using the *z* test \[[@pmed.1002974.ref038]\]. Mothers with missing values for maternal age at delivery were excluded from the adjusted models. Individuals surviving beyond the end of the study period were censored at March 31, 2016.

Age-standardized all-cause mortality rates were estimated for England and Ontario using the direct method of standardization and the Canadian 2006 Census as the standard population. We present age-standardized all-cause mortality rates stratified by maternal age at delivery (excluding those with missing age information), neighbourhood income quintile (Q1 \[most deprived\] versus Q2--Q5 due to low numbers of deaths in the most affluent quintiles), urban/rural residence, previous addiction-related or other mental-health-related hospitalization, Charlson comorbidity index (0 versus 1+ due to low numbers of deaths in the 2+ category for NAS mothers), and infant discharge to social service out-of-home care.

### Cause-specific mortality {#sec014}

Ten-year cumulative incidence of death was calculated for each cause of death category with consideration of other causes of death as competing risk events using Gray's test for the homogeneity of 2 or more cumulative incidence functions. Individuals surviving beyond the end of the study period were censored at December 31, 2014, for this particular analysis.

Statistical analyses were performed using Stata version 15 for England data and SAS version 9.4 statistical software for Ontario data in a Unix environment. *p*-Values for age-standardized all-cause mortality and cause-specific mortality were derived using the *z* test.

ICES is a prescribed entity under section 45 of Ontario's Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to, or planning for all or part of the health system. Projects conducted under section 45, by definition, do not require review by a research ethics board. This project was conducted under section 45, and approved by the ICES Privacy and Legal Office. Research ethics approval was granted by the Hospital for Sick Children Research Ethics Board for Ontario analyses. The English analyses were exempt from UK NHS Research Ethics Committee approval because it involved the analysis of de-identified administrative data.

Results {#sec015}
=======

Cohort characteristics of mothers in England and Ontario {#sec016}
--------------------------------------------------------

After applying our inclusion criteria, there were 13,577 and 4,966 mothers of infants with NAS and 4,205,675 and 929,985 control mothers in England and Ontario, respectively. Baseline characteristics are described in [Table 2](#pmed.1002974.t002){ref-type="table"}. In both jurisdictions, the majority of mothers had no previous recorded hospital birth (lookback to April 1, 1997) and lived in urban areas. Compared to controls, a larger proportion of mothers of infants with NAS lived in neighbourhoods in the lowest income quintile (37.3% versus 23.5% in England and 44.9% versus 22.9% in Ontario; *p \<* 0.001 for both jurisdictions); mothers of infants with NAS were on average younger than controls, and, in Ontario, a higher proportion were teenage mothers (9.8% versus 3.7%; *p \<* 0.001). Mothers of infants with NAS were more likely to have higher comorbidity scores (1 or 2+ on the Charlson comorbidity index) than controls (21.2% versus 6.9% in England and 7.6% versus 1.7% in Ontario; *p \<* 0.001 for both jurisdictions), and a greater proportion also had a previous psychiatric hospitalization (13.5% versus 0.6% in England and 15.3% versus 1.1% in Ontario; *p \<* 0.001 for both jurisdictions). Infant discharge to care by social services was much more common among infants with NAS than among control infants in both England (9.7% versus 0.1%; *p \<* 0.001) and Ontario (15.2% versus 0.1%; *p \<* 0.001). We found no differences in neonatal mortality between infants with NAS and controls in Ontario, but a marginally higher rate among infants with NAS in England (0.3% versus 0.2% *p* = 0.01).

10.1371/journal.pmed.1002974.t002

###### Characteristics of mothers and infants at baseline, April 1, 2002 to December 31, 2012.

![](pmed.1002974.t002){#pmed.1002974.t002g}

  Characteristic                                                                                                 England                                             Ontario                                                                  
  -------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------ ----------------------------------------------------- ----------------
  **Mean (SD) maternal age at delivery, years**[\*](#t002fn002){ref-type="table-fn"}                             28.5 (5.6)                                          29.8 (6.1)         27.0 (6.1)                                            30.2 (5.6)
  **Maternal age at delivery, categorized**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                              
  ≤19 years                                                                                                      775 (5.7)                                           258,200 (6.1)      488 (9.8)                                             34,414 (3.7)
  20--34 years                                                                                                   10,712 (78.9)                                       3,041,112 (72.3)   3,815 (76.8)                                          683,910 (73.5)
  35+ years                                                                                                      1,869 (13.8)                                        898,110 (21.4)     663 (13.4)                                            211,661 (22.8)
  Missing                                                                                                        221 (1.6)                                           8,253 (0.2)        0 (0.0)                                               0 (0.0)
  **Time since last birth**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                              
  No previous birth since 1997                                                                                   6,944 (51.1)                                        2,692,743 (64.0)   2,322 (46.8)                                          568,109 (61.1)
  \<2 years                                                                                                      1,504 (11.1)                                        315,454 (7.5)      697 (14.0)                                            78,540 (8.4)
  2 to 5 years                                                                                                   2,761 (20.3)                                        840,237 (20.0)     1,366 (27.5)                                          238,227 (25.6)
  6+ years                                                                                                       2,368 (17.4)                                        357,240 (8.5)      581 (11.7)                                            45,109 (4.9)
  **Neighbourhood income quintile**[\*](#t002fn002){ref-type="table-fn"}[^†^](#t002fn003){ref-type="table-fn"}                                                                                                                                
  Q1 (lowest)                                                                                                    5,059 (37.3)                                        988,493 (23.5)     2,231 (44.9)                                          212,869 (22.9)
  Q2                                                                                                             3,487 (25.7)                                        898,448 (21.4)     1,043 (21.0)                                          187,607 (20.2)
  Q3                                                                                                             2,304 (17.0)                                        792,989 (18.9)     668 (13.5)                                            188,884 (20.3)
  Q4                                                                                                             1,622 (11.9)                                        747,224 (17.8)     599 (12.1)                                            189,978 (20.4)
  Q5 (highest)                                                                                                   1,105 (8.1)                                         778,521 (18.5)     425 (8.6)                                             150,647 (16.2)
  Q2--Q5                                                                                                         8,518 (62.7)                                        3,217,182 (76.5)   2,735 (55.1)                                          717,116 (77.1)
  **Area of residence**[\*](#t002fn002){ref-type="table-fn"}[^‡^](#t002fn004){ref-type="table-fn"}                                                                                                                                            
  Urban                                                                                                          12,217 (90.0)                                       3,573,814 (85.0)   4,164 (83.9)                                          841,133 (90.4)
  Rural                                                                                                          1,360 (10.0)                                        631,861 (15.0)     802 (16.1)                                            88,852 (9.6)
  **Charlson comorbidity index**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                         
  0                                                                                                              10,695 (78.8)                                       3,915,844 (93.1)   4,586 (92.3)                                          914,048 (98.3)
  1                                                                                                              2,606 (19.2)                                        272,330 (6.5)      304 (6.1)                                             12,325 (1.3)
  2+                                                                                                             276 (2.0)                                           17,501 (0.4)       76 (1.5)                                              3,612 (0.4)
  **Any psychiatric condition**[\*](#t002fn002){ref-type="table-fn"}                                             1,832 (13.5)                                        26,108 (0.6)       760 (15.3)                                            10,440 (1.1)
  Addiction-related[\*](#t002fn002){ref-type="table-fn"}                                                         1,396 (10.3)                                        8,922 (0.2)        318 (6.4)                                             1,411 (0.2)
  Other mental health[\*](#t002fn002){ref-type="table-fn"}                                                       566 (4.2)                                           18,055 (0.4)       572 (11.5)                                            9,490 (1.0)
  **Cesarean delivery**                                                                                          3,121 (23.0)[\*](#t002fn002){ref-type="table-fn"}   1,044,111 (24.8)   1,374 (27.7)[^NS^](#t002fn005){ref-type="table-fn"}   268,553 (28.9)
  **Pre-eclampsia/eclampsia**                                                                                    290 (2.1)[\*](#t002fn002){ref-type="table-fn"}      127,753 (3.0)      60 (1.2)[^NS^](#t002fn005){ref-type="table-fn"}       11,390 (1.2)
  **Gestational diabetes**[\*](#t002fn002){ref-type="table-fn"}                                                  48 (0.4)                                            36,276 (0.9)       181 (3.6)                                             48,893 (5.3)
  **Gestational hypertension**                                                                                   220 (1.6)[\*](#t002fn002){ref-type="table-fn"}      123,908 (3.0)      193 (3.9)[^NS^](#t002fn005){ref-type="table-fn"}      40,505 (4.4)
  **Gestational age at delivery**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                        
  \<34 weeks                                                                                                     671 (4.9)                                           92,155 (2.2)       318 (6.4)                                             18,825 (2.0)
  34 to 36 weeks                                                                                                 1,224 (9.0)                                         132,599 (3.2)      721 (14.5)                                            50,529 (5.4)
  37+ weeks                                                                                                      7,538 (55.5)                                        2,962,970 (70.5)   3,875 (78.0)                                          859,353 (92.4)
  Missing[^§^](#t002fn006){ref-type="table-fn"}                                                                  4,144 (30.5)                                        1,018,010 (24.2)   52 (1.1)                                              1,278 (0.1)
  **Infant discharged to social services**[\*](#t002fn002){ref-type="table-fn"}                                  1,316 (9.7)                                         4,446 (0.1)        753 (15.2)                                            1,265 (0.1)
  **Neonatal mortality**                                                                                         37 (0.3)                                            7,497 (0.2)        18 (0.4)[^NS^](#t002fn005){ref-type="table-fn"}       2,724 (0.3)

Data are number (percent) unless otherwise indicated. Neonatal mortality was statistically significantly different between cases and controls for England, at *p* = 0.01. *p*-Values for continuous variables were derived from ANOVA, while *p*-values for categorical variables were derived from Pearson's chi-squared test.

\*There was a statistically significant difference between cases and controls (*p* \< 0.001).

^†^Missing values for neighbourhood income quintile for England (0.82% and 0.57% of cases and controls, respectively) and Ontario (2.11% and 0.40% of cases and controls, respectively) were included in the lowest quintile (Q1).

^‡^Missing values for area of residence for England (1.1% of cases and 0.54% of controls) and Ontario (0.08% and 0.02% of cases and controls, respectively) were included in the urban residence category.

^NS^There was no statistically significant difference between cases and controls.

^§^Gestational age is not a mandatory field reported to NHS Digital in England.

NAS, neonatal abstinence syndrome.

Risk of death among mothers of infants born with NAS {#sec017}
----------------------------------------------------

From 2002 to 2016, there were 112,890 total person-years of follow-up for mothers of infants with NAS in England (34.9 million for controls) and 35,740 total person-years of follow-up for mothers of infants with NAS in Ontario (7.9 million for controls). The mean duration of follow-up was 8.4 years (England) and 7.2 years (Ontario) for NAS mothers and 8.2 years (England) and 8.6 years (Ontario) for controls. Crude mortality rate for mothers of infants with NAS was 5.01 (95% CI 4.62--5.44) per 1,000 person-years in England and 4.28 (95% CI 3.63--5.02) per 1,000 person-years in Ontario. In both jurisdictions, the crude cumulative mortality incidence (superimposed on the survival curves in [Fig 1](#pmed.1002974.g001){ref-type="fig"}) was significantly different between mothers of infants with NAS and controls. In England, 5- and 10-year mortality (95% CI) was 1.81% (1.59%--2.05%) and 5.13% (4.69--5.62%), respectively, for mothers of infants with NAS and 0.15% (0.15%--0.16%) and 0.42% (0.41--0.43%), respectively, for controls (*p \<* 0.001 for 5- and 10-year mortality for NAS mothers versus controls); in Ontario, it was 1.85% (1.51%--2.28%) and 4.58% (3.81%--5.49%), respectively, for mothers of infants with NAS and 0.15% (0.15%--0.16%) and 0.40% (0.38%--0.41%), respectively, for controls (*p \<* 0.001 for 5- and 10-year mortality for NAS mothers versus controls). The decline in survival of mothers of infants with NAS over time was steady in both jurisdictions, with no clear inflection point or distinct period of risk.

![Survival curves for all-cause mortality---Crude (Kaplan--Meier curve) and adjusted (derived from Cox model) for maternal age at delivery, 2002 to 2016.\
Crude curves for England (A) and Ontario (C); adjusted curves for England (B) and Ontario (D). Red, neonatal abstinence syndrome (NAS) mothers; blue, controls. The adjusted survival curve for the England controls is a 10% sample of the full control population. *p \<* 0.001 for a difference in all-cause mortality between NAS mothers and controls for the overall study period (crude and adjusted), 5-year mortality (crude), and 10-year mortality (crude) for England and Ontario. Mortality rates superimposed on figures are accompanied by 95% confidence limits presented in parentheses.](pmed.1002974.g001){#pmed.1002974.g001}

[Table 3](#pmed.1002974.t003){ref-type="table"} outlines age-standardized mortality rates overall and stratified by clinical and demographic characteristics for the whole study period. In both jurisdictions, rates of death were higher among mothers of infants with NAS compared to controls across most risk groups. Differences in rates were not significant (95% confidence intervals overlapped) for NAS mothers and controls for those with a history of addiction-related admission (England and Ontario) or who had an infant discharged to social services (Ontario only) or who were 19 years old or under at delivery (Ontario only).

10.1371/journal.pmed.1002974.t003

###### Age-standardized all-cause mortality rates per 1,000 women, April 1, 2002, to March 31, 2016.

![](pmed.1002974.t003){#pmed.1002974.t003g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                England                  Ontario                                                                           
  --------------------------------------------- --------- -------------- --------- -------------- --------- ----- --------------- ------- ---------------- ---------
  **Overall**                                   566       41.7\          14,356    3.5\           \<0.001   153   33.3\           3,194   3.6\             \<0.001
                                                          (37.9--45.4)             (3.4--3.6)                     (27.6--39.9)            (3.5--3.8)       

  **Maternal age at delivery, years**                                                                                                                      

  ≤19                                           11        15.5\          682       2.7\           \<0.001   7     11.9\           167     5.1\             0.3
                                                          (5.1--25.8)              (2.5--2.9)                     (3.5--29.1)             (4.3--6.1)       

  20--34                                        439       40.5\          8,796     2.8\           \<0.001   119   31.9\           2,067   3.0\             \<0.001
                                                          (36.7--44.2)             (2.8--2.9)                     (26.3--38.3)            (2.9--3.2)       

  35+                                           116       65.4\          4,878     6.3\           \<0.001   27    39.5\           960     5.2\             \<0.001
                                                          (50.5--80.2)             (5.8--6.2)                     (22.7--64.1)            (4.8--5.6)       

  **Neighbourhood income quintile**                                                                                                                        

  Q1 (lowest)                                   228       47.6\          3,801     4.5\           \<0.001   71    37.7\           932     4.6\             \<0.001
                                                          (40.8--54.3)             (4.3--4.6)                     (28.2--49.4)            (4.3--5.0)       

  Q2--Q5                                        328       38.3\          10,555    3.3\           \<0.001   82    30.7\           2,262   3.4\             \<0.001
                                                          (33.8--42.9)             (3.2--3.4)                     (23.7--39.1)            (3.2--3.5)       

  **Area of residence**                                                                                                                                    

  Urban                                         526       43.1\          12,176    3.5\           \<0.001   130   33.6\           2,728   3.4\             \<0.001
                                                          (39.0--47.2)             (3.4--3.6)                     (27.5--40.8)            (3.3--3.6)       

  Rural                                         40        28.5\          2,180     3.4\           \<0.001   23    30.0\           466     5.4 (4.9--6.0)   \<0.001
                                                          (18.7--38.3)             (3.2--3.5)                     (16.7--49.8)                             

  **History of psychiatric hospitalizations**                                                                                                              

  Addiction-related                             109       78.6\          327       56.8\          0.01      16    58.0\           46      39.0\            0.3
                                                          (62.5--94.7)             (50.2--63.4)                   (31.4--98.1)            (27.5--53.6)     

  Other mental health                           41        64.7\          358       20.1\          \<0.001   29    55.3\           139     16.5\            \<0.001
                                                          (43.9--85.6)             (17.9--22.2)                   (35.5--82.2)            (13.5--20.1)     

  **Infant discharge to social services**       77        58.3\          83        22.5\          \<0.001   22    27.8\           30      32.9\            0.6
                                                          (44.2--72.3)             (17.3--27.6)                   (16.0--45.0)            (20.9--49.1)     

  **Charlson comorbidity index**                                                                                                                           

  0                                             400       37.1\          11,933    3.1\           \<0.001   123   27.8\           2,881   3.4\             \<0.001
                                                          (33.0--41.1)             (3.1--3.2)                     (22.4--34.1)            (3.2--3.5)       

  1+                                            166       56.3\          2,423     8.7\           \<0.001   30    80.8\           313     19.3\            \<0.001
                                                          (46.8--65.8)             (8.3--9.1)                     (52.6--118.8)           (16.9--22.0)     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Estimates were age-standardized to the 2006 Canadian population using the age groups 12--18, 19, 20--29, 30--34, 35--37, and 38--49 years for maternal age at delivery, and 12--21, 22--29, and 30+ years for the remaining characteristics.

NAS, neonatal abstinence syndrome.

The crude hazard ratio for all-cause mortality among mothers of infants with NAS was 12.1 (95% CI 11.1--13.2; *p \<* 0.001) in England and 11.4 (95% CI 9.7--13.4; *p \<* 0.001) in Ontario ([Table 4](#pmed.1002974.t004){ref-type="table"}). After adjustment for age, the hazard ratio increased for England and was unchanged for Ontario (England adjusted HR 13.0; 95% CI 11.9--14.1; *p \<* 0.001; and Ontario adjusted HR 11.4; 95% CI 9.7--13.4; *p \<* 0.001).

10.1371/journal.pmed.1002974.t004

###### All-cause mortality risks for mothers with infants with neonatal abstinence syndrome, crude and adjusted for maternal age at delivery, 2002 to 2016.

![](pmed.1002974.t004){#pmed.1002974.t004g}

  Model                                   England             Ontario                      
  --------------------------------------- ------------------- --------- ------------------ ---------
  Crude                                   12.1 (11.1--13.2)   \<0.001   11.4 (9.7--13.4)   \<0.001
  Adjusted for maternal age at delivery   13.0 (11.9--14.1)   \<0.001   11.4 (9.7--13.4)   \<0.001

[Table 5](#pmed.1002974.t005){ref-type="table"} presents results for cause-specific mortality between 2002 and 2014 (cause-specific data for 2015--2016 were not available in Ontario). Avoidable deaths were the most common cause of death among mothers of infants with NAS in both jurisdictions (accounting for \>85% in England and 75% in Ontario), with a 10-year cumulative incidence risk of 42.9 deaths per 1,000 population (95% CI 38.4--47.9) among English mothers and 30.8 deaths per 1,000 population (95% CI 24.1--38.8) among Ontario mothers. Intentional and unintentional injuries (e.g., transport injuries, unintentional falls) made up the majority of avoidable mortality in the mothers of infants with NAS in both jurisdictions.

10.1371/journal.pmed.1002974.t005

###### Cause-specific mortality per 1,000 population among mothers (10-year cumulative incidence risk), April 1, 2002, to December 31, 2014.

![](pmed.1002974.t005){#pmed.1002974.t005g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of deaths                                            England   Ontario                                                                                 
  --------------------------------------------------------- --------- -------------- ------- ------------ --------- ----- -------------- ------- ------------ ---------
  **Avoidable (excluding cancer)**                          393       42.9\          5,758   2.1\         \<0.001   93    30.8\          956     1.4\         \<0.001
                                                                      (38.4--47.9)           (2.0--2.1)                   (24.1--38.8)           (1.3--1.5)   

  Unintentional injuries                                    177       19.6\          1,132   0.4\         \<0.001   46    13.9\          285     0.4\         \<0.001
                                                                      (16.6--23.1)           (0.4--0.4)                   (9.7--19.3)            (0.4--0.5)   

  Intentional injuries                                      63        6.5\           1,298   0.5\         \<0.001   20    6.4\           312     0.5\         \<0.001
                                                                      (4.9--8.7)             (0.4--0.5)                   (3.8--10.4)            (0.4--0.5)   

  Drug use disorders                                        90        9.7\           701     0.3\         \<0.001   15    5.7\           45      0.1\         \<0.001
                                                                      (7.6--12.3)            (0.3--0.3)                   (3.1--9.9)             (0.1--0.1)   

  All other avoidable deaths                                63        7.8\           2,627   0.9\         \<0.001   12    4.8\           314     0.5\         \<0.001
                                                                      (5.9--10.2)            (0.9--1.0)                   (2.3--9.1)             (0.4--0.5)   

  **Unavoidable (excluding cancer)**                        42        4.2\           1,649   0.6\         \<0.001   19    8.5\           417     0.6\         \<0.001
                                                                      (3.0--5.9)             (0.5--0.6)                   (4.6--14.7)            (0.6--0.7)   

  **Cancer (avoidable and unavoidable)**                    16        1.6\           4,233   1.6\         1.00      10    3.3\           1,113   1.8\         0.2
                                                                      (1.5--1.7)             (0.9--2.8)                   (1.6--6.3)             (1.7--1.9)   

  **Missing cause**[^a^](#t005fn001){ref-type="table-fn"}   ≤10       ---            ≤10     ---          ---       ≤ 5   ---            139     0.2\         ---
                                                                                                                                                 (0.2--0.2)   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Privacy legislation requires suppression of cell sizes \<11 in England and \<6 in Ontario.

NAS, neonatal abstinence syndrome.

Discussion {#sec018}
==========

In this large population-based study across 2 countries, 1 in 20 mothers of infants with NAS died within 10 years of delivery---a mortality risk that was 11--12 times higher than for control mothers. Findings were consistent across both jurisdictions. For virtually all causes of death, mortality rates were substantially higher for mothers of infants with NAS than for controls, with the majority of deaths attributable to avoidable causes such as intentional and unintentional injuries. We also identified universally high mortality rates among mothers who had a history of hospitalization for addiction, irrespective of whether or not their infant had NAS. We found no evidence of a high risk period in the 1--2 years after birth (corresponding to the period typically targeted by public health nursing or other support for high-risk families) for maternal deaths in the NAS group.

Other population-based studies report increased perinatal maternal mortality in mothers using opioids \[[@pmed.1002974.ref005],[@pmed.1002974.ref016],[@pmed.1002974.ref017]\] and longer-term risk in mothers with alcohol or drug misuse during pregnancy \[[@pmed.1002974.ref020],[@pmed.1002974.ref022]\] ([Table 1](#pmed.1002974.t001){ref-type="table"}). None of these studies address long-term all-cause mortality for mothers of NAS-affected infants as we have done. High mortality rates have been reported for non-pregnant populations of female opioid users. Notably, 3 large-scale studies present crude mortality rates per 1,000 person-years of 6.5 (95% CI 6.1--6.9) in New South Wales \[[@pmed.1002974.ref039]\], between 7.5 and 13.9 in opioid-using women aged 15--44 years in California \[[@pmed.1002974.ref029]\], and 12.2 (95% CI 10.3--14.4) and 19.7 (95% CI 15--25.8), respectively, for female users of heroin and other opioids in Denmark \[[@pmed.1002974.ref040]\]. Our crude mortality rates per 1,000 person-years for mothers with infants with NAS of 5.01 (95% CI 4.62--5.44) in England and 4.28 (95% CI 3.63--5.02) in Ontario are comparatively lower, which is likely driven in part by a relatively younger age distribution in our study population. For example, in the New South Wales study, Degenhardt et al. included all ages and reported increasing mortality rates with older age. The higher risk of all-cause mortality we report is not surprising and has been shown in other marginalized groups or those with mental health problems \[[@pmed.1002974.ref021],[@pmed.1002974.ref041]\]. In particular, unintentional injury deaths (which include those related to victimization) predominate and may result from social vulnerability or misclassification of injuries that are intentional \[[@pmed.1002974.ref042]--[@pmed.1002974.ref046]\].

In our study, the high rate of premature mortality among the mothers of infants with NAS was mirrored by high rates for the mothers of control infants discharged to social services and for mothers with a history of hospitalization for addiction. Other studies have demonstrated maternal well-being declining in association with the loss of a child to foster care \[[@pmed.1002974.ref042],[@pmed.1002974.ref047]\], whereas retaining care of the child may help facilitate treatment \[[@pmed.1002974.ref048]\]. An estimated 7%--20% of NAS-affected infants do not return home with their mother at the time of postnatal discharge from hospital \[[@pmed.1002974.ref049]--[@pmed.1002974.ref052]\], which is similar to the percentage in our study (10%--15%). However, these figures may not reflect the much higher cumulative risk of foster care placements occurring later in childhood \[[@pmed.1002974.ref053]\]. Our findings also mirror the growing body of literature describing the constellation of psychosocial risk factors linking mental illness, addiction, and social adversity \[[@pmed.1002974.ref043],[@pmed.1002974.ref054]\] and suggest the need for multifaceted support for these mothers irrespective of whether their children are living with them.

The longitudinal and population-based nature of this study, its size, and comparison of similar universal healthcare systems are strengths. Limitations include potential linkage error, misclassification of mothers using opioids whose babies did not develop NAS, and lack of direct measures of maternal opioid use or treatment, or other substance misuse, which may underestimate the burden of mortality in mothers with opioid use within our study or make findings less generalizable to opioid-using mothers whose infants do not have NAS or who live in other jurisdictions with other approaches to treatment and available supportive services. In the extract of English hospital data, 96% of live births were matched to maternal records, but linkage was lower (88%) for infants with NAS. Comparison of the characteristics of these English infants with NAS by linkage status indicated an association between non-linkage and both longer hospital stays and greater risk of placement in out-of-home care \[[@pmed.1002974.ref055]\], with the implication that our results may underestimate the risk of death among women with opioid use. Our results reflect the subset of mothers with prenatal opioid exposure who gave birth to an infant with NAS, and as such they likely underestimate the true risk of maternal mortality associated with prenatal opioid use. However, we also describe mortality in mothers without an infant with NAS, but who received care for mental illness and addictions, thus broadening the scope for generalizability. Our study cohort may also include the rare cases of NAS related to withdrawal from other substances \[[@pmed.1002974.ref056]\] or from postnatal opioid use ("iatrogenic NAS") \[[@pmed.1002974.ref057]\], but data on these other exposures were not available.

Our study has implications for research, practice, and policy to improve maternal and, arguably, child outcomes related to prenatal opioid use. Enhanced treatment programs for opioid dependence that integrate maintenance therapy, psychotherapy, reproductive health, and obstetric care have been found to be effective in reducing substance misuse, unplanned pregnancies, and obstetric complications during the perinatal period \[[@pmed.1002974.ref058]\]. Some evaluations of programs supporting mothers with opioid use and their children suggest that multifaceted services addressing health, addiction, housing, and parenting needs can improve parenting capacity and attachment and reduce child apprehension \[[@pmed.1002974.ref056],[@pmed.1002974.ref059]--[@pmed.1002974.ref064]\]. However, rigorous evidence on interventions promoting long-term support is limited and should be a research and policy priority. New funding for child welfare agencies in the US to provide services related to mental health, addictions, and parenting in response to the growing numbers of mothers using opioids is an opportunity for evaluation of different models of support \[[@pmed.1002974.ref065]\]. Most current home-visiting programs target only families with children and only for a short period of time. Our findings suggest that interventions need to extend past the early postpartum period and include mothers whose children may not return home. Finally, the findings from our study also indicate that studies and surveillance focused only on deaths directly attributable to opioid overdose will miss the full extent of the problem, given the importance of deaths due to unintentional and intentional injuries, not all of which involve opioids.

In conclusion, while much attention and research on NAS has focused on infant and child outcomes in isolation, our study is the first population-based analysis to our knowledge of long-term maternal mortality following the birth of an infant with NAS. The findings provide a stark reminder of the vulnerability and sustained poor outcomes of these mothers. Policy responses to the current opioid epidemic will require effective strategies for risk mitigation and ongoing support for families affected by opioid use. Large-scale linkage of health and social care administrative data would facilitate ongoing research, program evaluation, and surveillance.
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\(1\) On page 4 of introduction (no line numbers) it is stated that \"risks may differ given patterns of opioid use in the current global epidemic\" but I don\'t think the patterns of use is tested within this study, and I don\'t believe that there is evidence within report that the effect of opioid use would differ depending on the population prevalence/patterns being assessed as opposed to the effects on an individual.

\(2\) The study population of mothers seems to be relevant only in terms of the children providing a proxy measure of the opioid status, and that as stated on page 10 there was \"no difference in neonatal mortality between infants with NAS and controls\". As such, it may be relevant to expand further on how comparable the results from this study are in terms of mortality rates to other studies that exist and have taken a more general population but with different issues of accurately recording opioid use as suggested in introduction (eg lack of prescription data, measuring illicit use).

\(3\) Further detail is in my opinion necessary to justify the non-consideration of other covariates in the statement of statistical analysis section that \"..other covariates may be on the causal pathway\". While this could be a justification for excluding terms as adjustments in the model, there is no evidence within the report of the proposed directions of causality (eg in graph), and I would consider that some of the other available covariates (eg deprivation status) could potentially be a confounding factor as opposed to being caused in the first instance by opioid use.

\(4\) Given the categorisation of age and charlson score in some of the descriptive tables, it would be useful to confirm if in fact that continuous measures are used for the models that have been fitted as this could provide a more appropriate model than if they have been categorised in a relatively arbitrary way.

\(5\) Individuals would technically not be \"censored at death\" as for all cause-mortality death is the outcome/event of interest and there would be no time after death to censor (as there would be with the end of follow up)

\(6\) To asses rates by factors not in the models stratified analysis has been done, but this is without first having tested interaction terms of the terms under consideration and opioid group which would provide more robust interpretation of whether there are any genuine sub-group differences.

\(7\) In figure 1 results from adjusted models are shown in Kaplan Meier plots, but it is unclear exactly what results this is showing. Potentially it is for the average age and average charlson score across the entire study, and if so this could be made clear within the figure caption.

\(8\) The grouping of Q2-Q5 for neighborhood income quarintile in table 3 seems somewhat arbitrary instead of using the quintiles directly, particularly as missing data has been recoded into the lowest level which could also have an effect on how this comparison would be interpreted. Although the assumptions for recoding the missing income-quintile or rural/urban in general seems reasonable, the robustness of the results to these assumptions and whether there is any systematic reasons for why there would be missing data if not just random would be useful to comment on.

\(9\) In the discussion section on page 16, it is noted that there is \"potential for impact to improve maternal and child outcomes\", and similarly on page 18 \"potential implications for their children\", but within the analysis done as part of this article it is only stated that there is no difference in mortality between NAS and control children in terms of mortality and no other child outcomes were considered or summaries shown. Based on the data from this study alone the statements on child outcomes are therefore not supported. However, there are also summaries in the discussion section relating to children not presented in the main results of the study (\"..10-15% NAS affected infants do not return home with mother..\", \"greater risk of placement in out of home care\") suggesting that there potentially is data available that could be shown to support the statement and give greater clarity on the outcomes for children.

Reviewer \#2: Thank you for the opportunity to review this interesting manuscript.

1\. I was a little confused about the study period and the look-back time, when reading through the first time. Was there linked hospital data back to 1 April 1997 for all? Was the look-back a consistent 5 years for all, or was it back to 1997 for all? All-cause mortality had data up to March 31 2016, so only those from 2002 to 2006 had a full 10 years of follow-up, is that correct? Was 10 years the maximum follow-up time for each individual? Please add further details in the methods. Please specify the average follow-up time per person (split by jurisdiction as well as NAS and controls) in the Results section.

2\. The abstract background discusses the pregnancy and delivery settings as an opportunity to access support, and potentially assist new mothers with opioid addiction. However, I couldn\'t see mention of this in the Introduction. If this is an important theme of the paper, then I think it needs further exploration. What, if any, studies have shown an impact of targeting pregnant women or mothers with opioid addiction? Are women on methadone or other opioid-replacement therapy better off than those who are not?

3\. Please state the number and proportion of all the missing data noted in the methods, e.g. income, area of residence and age. The authors state that missing values for neighbourhood income quintile were put in the lowest income quintile, and that missing area of residence was categorised into urban. Including the missing data in one category will bias your findings towards the null, as the missing presumably include a proportion of values in all categories. I would suggest either removing the missing, if the proportion is very small, or using principled missing data methods such as multiple imputation or full information maximum likelihood, if the missing is more substantial. And why is the missing data for gestational week of birth so high in the English cohort?

4\. The Charlson Comorbidity index is a weighted score based on the relative risk of mortality. The index is not a continuous variable, nor a count of comorbidities (please revise the footnote on Table 2). Using it as a continuous variable (e.g. reporting mean and including it in the Cox regression as a continuous variable) suggests that the relative impact on mortality from 0 to 1 comorbidity score is the same as that from 4 to 5, for example. What is the justification for using it as a continuous variable? Has the functional form been tested and shown to be linear?

5\. I agree that it is important to control for other underlying causes of death, not related to the possible opioid addiction, but there are some aspects of the Charlson score that are probably on the causal pathway, like HIV/AIDS and liver disease. I think a directed acyclic graph of the theoretical relationships between the variables and the mortality outcome would make the assumptions about the causal pathways explicit.

Minor comments:

Page 7, para 3, line 7: Suggest removing \"young\", as the extreme values are young and old.

Page 7, para 3, line 8: \"Missing values for neighbourhood income quintile\" should be followed by \"were\" not \"was\".

Page 12, para 1, line 3: I understand the intent of this sentence but on first read, it sounds like the cumulative mortality was similar for those with NAS and controls. Suggest rewording.

Table 2 - The percentage of primiparous women in the control groups looks very high. A quick look for other studies using Ontario or Toronto data, shows the proportion of primips is between 39 to 47%, not close to 60%. (E.g. Park et al, 2015, JOGC; Booth et al, 2017, CMAJ). I did not search for English studies.

Table 2 - I would be interested in whether the preterm births are planned or spontaneous. Is it possible to split this out?

Page 17, para 2, line 2: What is the expected impact of these limitations on the mortality outcomes?

Page 18, para 1, line 6: Are there differences between England and Ontario really a source of \'bias\', if the data are never combined?

Reviewer \#3: This is a very interesting and important study looking at the relationship of NAS (using it as a marker of OUD in pregnancy) in the infant to all-cause maternal mortality in the years following delivery. It is well-executed. The strengths and limitations are well-delineated. The abstract is clear and reflects the findings in the paper. The discussion and implications to public health were well-stated.

I appreciated the summary of the introductory literature in table 1

Suggestions for revision

1\. Table 2 would be strengthened by the addition of p-values to each variable.

2\. Supplementary table 3 is so important. I would move it to the body of the paper.

3\. Also Tables 3 and 4 would be strengthened by aOR.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1002974.r002

Author response to Decision Letter 0

17 Sep 2019

###### 

Submitted filename: 00_Response to Reviewers_PLOS Med NAS Paper_FINAL.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1002974.r003

Decision Letter 1

Gaynor-Brook

Louise

Senior Editor

© 2019 Louise Gaynor-Brook

2019

Louise Gaynor-Brook

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9 Oct 2019

Dear Dr. Guttmann,

Thank you very much for re-submitting your manuscript \"Long-term mortality in mothers of infants with neonatal abstinence syndrome: A population-based parallel-cohort study in England and Ontario, Canada\" (PMEDICINE-D-19-02772R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by one of the reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

\*PLEASE NOTE: we have a very close deadline for inclusion in the substance abuse special issue, which publishes throughout November and so please do submit as soon as possible to allow every opportunity for this to make the deadline, but not before you hear from my colleagues in production who will be in touch in the next couple of days with formatting edits they require - please do not resubmit until you here from them too and combine all edits into one resubmission.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Oct 16 2019 11:59PM.

Sincerely,

Clare Stone

for

Louise Gaynor, MBBS PhD

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Abstract - Please add p values to all quantifiable data and where 95% Cis are provided (also throughout main text and tables)

Data statement -- Ontario date -- we need a point of contact that isn't an author, per PLOS data policy.

Author summary --please add it into the main text immediately after the abstract and remove the Supp file containing it. In addition, it's quite long and so I suggest you remove:

• Only one recent study from the United States has explored death rates in women who took opioids in pregnancy, but solely in the first year and focused only on opioid-related deaths

And

• Surveillance of the harm of the opioid crisis should measure all types of mortality, not just that related to opioid overdoses, and jurisdictions should capitalize on available sources of health, social and demographic administrative data to monitor and evaluate programs

In your author summary, you say "Mothers with infants with versus without NAS were more likely to be teenagers" yet table shows that iin fact age 20-34is the largest number of NAS cases for both cohorts and fololowed by age 35+ and then te4enagers. Have I misunderstood table 2? If not, please remove declamatory language from the author summary.

Page 21 (our study is the first population-based analysis) -- to our knowledge..

Comments from Reviewers:

Reviewer \#2: Thank you to the authors for responding to my queries and comments. I only have one minor additional comment.

I think that the current description of the random selection of one birth for each mother still needs further clarification. As a suggestion, perhaps:

\"We restricted the cohort to singleton births and if a woman had more than one livebirth delivery during the study period, one delivery was chosen at random as the focus of the study. Thus, a delivery date was selected at random and used as the study entry point for the mother (referred to as index delivery) and subsequent deliveries were ignored.\"

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1002974.r004
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21 Oct 2019

Dear Dr. Guttmann,

On behalf of my colleagues and the academic editor, Dr. Louisa Degenhardt, I am delighted to inform you that your manuscript entitled \"Long-term mortality in mothers of infants with neonatal abstinence syndrome: A population-based parallel-cohort study in England and Ontario, Canada\" (PMEDICINE-D-19-02772R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Louise Gaynor, MBBS PhD

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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